Cytox debuts genetic biomarker research tool to test for Alzheimer’s risk

Cytox debuts genetic biomarker research tool to test for Alzheimer’s risk

The U.K.’s Cytox has launched the research use of its variaTECT genetic biomarker test for assessing the risk of Alzheimer’s disease.

The test, known as the variaTECT SNP (single nucleotide polymorphism) array, provides a simple blood-based research test. It features a comprehensive panel of Alzheimer’s informative SNPs to assist research and new drug discovery studies, and can help users in the pharma industry reduce the screening failure rate in identifying amyloid positive subjects for recruitment into clinical trials, the company said.

“For Alzheimer therapy to work effectively, we need to start to treat the disease very early,” John Hardy, chair of Molecular Biology of Neurological Disease, UCL Institute of Neurology, London, said in a statement. “Genetic analysis is the most effective way of deciding who should be assessed for early disease. For this, we need to achieve an AUC of close to 80 percent… and this is just where the current array performs.”

See the article in full at

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.